Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

CAR-T therapy Follow-Up study shows no new safety surprises

NCT ID NCT04488354

First seen Apr 22, 2026 · Last updated Jun 05, 2026 · Updated 7 times

Summary

This study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatment. Researchers also looked at how well the cancer was controlled over time. This was a safety-focused follow-up, not a test of a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • Sarah Cannon Research Institute - Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute - Texas Transplant Institute

    San Antonio, Texas, 78229, United States

  • University of California at San Diego

    San Diego, California, 92093, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina, 27157, United States

  • Weill Cornell Medical College - New York Presbyterian Hospital

    New York, New York, 10065, United States

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell neoplasm Burkitt lymphoma diffuse large B-cell lymphoma follicular lymphoma hematopoietic and lymphoid system neoplasm Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma neoplasm Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.